Physician profile
Gregory W Pearson
NPI 1699779108
$4,951.73
in general payments reported to CMS, 2019-2025
20 companies · $853 in 2025
The $853 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $538 · 2021: $189 · 2022: $327 · 2023: $1,266 · 2024: $1,009 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,937 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,937.49 |
| Education | $190.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $813.67 | 2019-2025 | |
| Progenacare Global, LLC | $730.34 | 2023 | |
| Merz North America, INC. | $661.74 | 2019-2020 | |
| Galderma Laboratories, L.P. | $657.61 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $503.34 | 2019-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $358.18 | 2023-2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $254.35 | 2019-2025 | |
| Janssen Biotech, INC. | $232.69 | 2019-2025 | Tremfya |
| Genzyme Corporation | $148.35 | 2024-2025 | |
| Incyte Corporation | $124.98 | 2024 | Opzelura |
| Pfizer INC. | $83.80 | 2024 | |
| Novartis Pharmaceuticals Corporation | $72.11 | 2019-2023 | |
| Lilly USA, LLC | $68.63 | 2019-2021 | |
| Leo Pharma INC. | $64.42 | 2019-2024 | Adbry |
| Genentech USA, INC. | $59.99 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $43.11 | 2025 | Bimzelx |
| Amgen INC. | $22.52 | 2023 | Otezla |
| Almirall LLC | $20.40 | 2019 | |
| Lnhc, INC | $16.10 | 2025 | Zelsuvmi |
| E.R. Squibb & Sons, L.L.C. | $15.40 | 2023 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.